Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327792 | 0.85 | MTNR1A (0.59) | MTNR1AMTNR1BCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL2327788 | 0.85 | MTNR1A (0.59) | MTNR1AMTNR1BCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL15499312 | 0.85 | MTNR1A (0.51) | MTNR1AMTNR1BCYP1A2MMEALDH1A1 | |
| SCHEMBL26521147 | 0.84 | CYP1A2 (0.55) | MTNR1AMTNR1BCYP1A2MMEALDH1A1 | |
| SCHEMBL20021560 | 0.84 | MTNR1A (0.57) | MTNR1AMTNR1BCYP1A2CTSSCTSK | |
| SCHEMBL497369 | 0.83 | CYP1A2 (0.68) | CYP1A2MMELTA4H | |
| SCHEMBL4724923 | 0.81 | CYP1A2 (0.65) | CYP1A2MMELTA4H | |
| SCHEMBL107422 | 0.81 | CYP1A2 (0.65) | CYP1A2MMELTA4H | |
| SCHEMBL40705 | 0.81 | CYP1A2 (0.65) | CYP1A2MMELTA4H | |
| SCHEMBL2588080 | 0.81 | CYP1A2 (0.65) | CYP1A2MMELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2967066-B1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2385763-B1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AERPIO THERAPEUTICS INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20170319602-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-9440963-B2 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160008327-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | EyePoint, Inc. | 2016-01-14 | — | — | US | disclosed |
| US-9174950-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9096555-B2 | Methods for treating vascular leak syndrome | AERPIO THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-8883832-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2014-08-28 | — | — | US | disclosed |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | SHALWITZ ROBERT (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2012047966-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AKEBIA THERAPEUTICS INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | MTNR1A 2436/4885MTNR1B 1098/4885CYP1A2 4131/4885 |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | MTNR1A 1155/4885MTNR1B 1364/4885CYP1A2 3978/4885 |
| US-20170319602-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | MTNR1A 375/4885MTNR1B 685/4885CYP1A2 4763/4885 |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | MTNR1A 592/4885MTNR1B 685/4885CYP1A2 4824/4885 |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | MTNR1A 844/4885MTNR1B 1314/4885CYP1A2 4700/4885 |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | MTNR1A 2436/4885MTNR1B 1098/4885CYP1A2 4131/4885 |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | MTNR1A 1155/4885MTNR1B 1364/4885CYP1A2 3978/4885 |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | MTNR1A 844/4885MTNR1B 1314/4885CYP1A2 4700/4885 |
| US-20160008327-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | TSG101, MMP8, EPCAM | MTNR1A 1834/4885MTNR1B 1706/4885CYP1A2 3083/4885 |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | MTNR1A 2436/4885MTNR1B 1098/4885CYP1A2 4131/4885 |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | MTNR1A 375/4885MTNR1B 685/4885CYP1A2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.